---
title: Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive
  acute leukemia
date: '2024-10-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39374521/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241007200551&v=2.18.0.post9+e462414
source: Blood
description: Dasatinib is effective treatment for Philadelphia chromosome-positive
  (Ph+) acute leukemia but some patients develop resistance. Combination treatment
  with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses
  and prevent the emergence of dasatinib-resistant clones. In this phase 1 study (NCT03595017),
  24 adults with Ph+ acute lymphoblastic leukemia (ALL, n=22; p190, n=16; p210, n=6)
  and chronic myeloid leukemia in lymphoid blast crisis (CML-LBC, n=2) were ...
disable_comments: true
---
Dasatinib is effective treatment for Philadelphia chromosome-positive (Ph+) acute leukemia but some patients develop resistance. Combination treatment with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses and prevent the emergence of dasatinib-resistant clones. In this phase 1 study (NCT03595017), 24 adults with Ph+ acute lymphoblastic leukemia (ALL, n=22; p190, n=16; p210, n=6) and chronic myeloid leukemia in lymphoid blast crisis (CML-LBC, n=2) were ...